Clinical Trial Update: A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating glatiramer acetate 40 mg three times weekly versus placebo in relapsing-remitting multiple sclerosis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GLATIRAMER ACETATE (GLATIRAMER ACETATE)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2018-10-09